AI Drug Molecule Design Engine PharmaForge Launches: Designing Novel Compounds from Scratch Instead of Screening Libraries
UK-based DeepPharma releases PharmaForge drug design engine, achieving for the first time the ability to design entirely novel molecular structures from scratch based on target protein 3D structures.
London-based DeepPharma today officially released PharmaForge, an AI drug design engine capable of designing entirely novel molecular compounds from the molecular level. Unlike traditional virtual screening methods that search existing molecular libraries, PharmaForge directly generates previously non-existent molecular structures based on the target proteins 3D structure and required pharmacokinetic properties.
PharmaForge uses a diffusion model-based molecular generation architecture combined with quantum chemistry calculations to verify the stability of generated molecules. DeepPharma CSO Dr. Emma Richards reported that 78% of 100,000 novel molecules generated in testing passed computational chemistry stability verification, far exceeding the 23% rate of previous comparable systems.
The company has partnered with Pfizer and AstraZeneca for two undisclosed targets. Preliminary in vitro experiments show PharmaForge-designed candidate molecules have approximately 3x higher binding affinity than traditionally screened candidates. DeepPharma plans to initiate the first clinical trial based on a PharmaForge-designed molecule by end of 2030.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.